Status and phase
Conditions
Treatments
About
The primary objective of this study is to demonstrate the feasibility of evaluating SAMe tolerability, analgesic benefits, and daily functional improvement in patients with osteoarthritis of the hands compared to placebo. The secondary objective of this study is to generate preliminary data on discomfort, function, quality of life in patients with osteoarthritis of the hands when taking SAMe compared to placebo.
Full description
At week 0, all patients giving written informed consent and meeting eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to SAMe (400mg orally, twice daily) or placebo (400mg, twice daily) for 8 weeks. Followed by a one week wash out period followed by another 8 weeks of SAMe (400mg, twice daily) or placebo (400mg, twice daily) for 8 weeks (whichever was not given during the first 8 week period).
Participants will complete weekly surveys during the entire study regarding hand discomfort, functional limitations and side effects
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Current primary care provider within the Dartmouth Health system
Office visit at Dartmouth Health in the past 3 years
Participants must be 40 or older at the time of signing the informed consent
Participants have discomfort or functional limitations of one or both hands AND either:
Patients taking OTC or prescription analgesics who are willing to stop their current analgesics for two weeks prior to study entry and remain off those medications over the course of the study
*Objective inclusion criteria (see poster schematic)
Swelling or deformity of 2 of the following ten joints: the 2nd and 3rd distal interphalangeal (DIP) of each hand, the 2nd and 3rd proximal interphalangeal (PIP) of each hand, and the 1st carpometacarpal joints of both hands.
Exclusion criteria
Patients taking prescription medications other than NSAIDs for their OA who are unable to stop their medication
Patients with diagnoses of arthritis from conditions other than OA
Patients whose symptomatic joint is an artificial joint
Patients with Bipolar Disorder
Patients taking any of the following medications at study entry OR starting any of these medications during the study period:
The participant has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal